Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KayakerBC

Rank: Treasurer [?]

Points: 1691 [?]

Votes: 23 Score: 2.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

in response to

Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

KOO-KOO2

posted on Jan 27, 2023 09:43AM

Halted Study
Biological: Pembrolizumab
Drug: Enzalutamide
Procedure: Androgen Deprivation Therapy (ADT)

Merck
"....The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. No new safety signals were identified; however, the combination was associated with a higher incidence of Grade 3-5 adverse events and serious adverse events compared to the control arm...."

ZEN-3694 Study
Drug: BET Bromodomain Inhibitor ZEN-3694
Drug: Enzalutamide
Biological: Pembrolizumab

Given that the ZEN study also includes both Enzalutamide and Pembrolizumab, why are similar side effects not a possible concern in the ZEN study?

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply